Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Genedrive Plc LSE:GDR London Ordinary Share GB00B1VKB244 ORD 1.5P
  Price Change % Change Share Price Shares Traded Last Trade
  9.50 48.72% 29.00 3,630,709 16:35:04
Bid Price Offer Price High Price Low Price Open Price
27.00 30.00 30.00 19.50 19.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 2.36 -4.52 -14.00 10
Last Trade Time Trade Type Trade Size Trade Price Currency
16:36:35 O 50,000 29.50 GBX

Genedrive (GDR) Latest News (3)

More Genedrive News
Genedrive Takeover Rumours

Genedrive (GDR) Discussions and Chat

Genedrive Forums and Chat

Date Time Title Posts
30/3/202023:12Genedrive (GDR) One to Watch 26
27/3/202012:11Still waiting....159

Add a New Thread

Genedrive (GDR) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
17:11:5029.5050,00014,750.00O
16:41:3730.0050,00015,000.00O
16:36:3629.2530,0008,775.00O
16:32:5828.3175,00021,229.13O
16:17:4529.2625,0007,315.00O
View all Genedrive trades in real-time

Genedrive (GDR) Top Chat Posts

DateSubject
30/3/2020
09:20
Genedrive Daily Update: Genedrive Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker GDR. The last closing price for Genedrive was 19.50p.
Genedrive Plc has a 4 week average price of 8.75p and a 12 week average price of 6.50p.
The 1 year high share price is 38.50p while the 1 year low share price is currently 6.50p.
There are currently 34,000,506 shares in issue and the average daily traded volume is 2,907,600 shares. The market capitalisation of Genedrive Plc is £9,860,146.74.
25/3/2020
08:48
the ghost who walks: Yes it's amazing.Glad to be proved wrong, hoping that they now deliver and then raise at a much much higher share price.Note it's still below 20 which is bizarre.
17/10/2017
14:37
walbrock82: Despite the rise in today’s share price, Genedrive’s results are poor. Revenue missed their £7m forecast and net losses widened to £6.4m, greater than their sales of £5.8m. The problems facing this diagnostic business is two-fold: -One R&D expenses account for 90% of group sales (normally you would expect 20%). Also, it grows larger as sales increase. -Two staff costs represent half of sales. Also, 40% of group sales is reliance on grant funding which is a volatile source of income. But, right now it is helping to mask internal sales weakness within the business. Those who participate in last year placing at 80p is down by 55%. For more Genedrive analysis and other analysis on companies’ results, click http://bit.ly/2hLViFb
Genedrive share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
GDR
Genedrive
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200330 23:28:26